ProjectIdentification and development of smallmolecule inhibitors targeting Salmonella type IIIsecretion systems
Basic data
Title:
Identification and development of smallmolecule inhibitors targeting Salmonella type IIIsecretion systems
Duration:
01/01/2023 to 28/02/2026
Abstract / short description:
The worldwide rise of antibiotic-resistant bacterial strains represents a serious
threat for the treatment of infections, in particular for treatment of GI pathogens,
as antibiotics affect the GI tract three-fold: emergence of resistance of GI
pathogens, disruption of colonization resistance of the intestinal microbiota, and
emergence of antibiotic-resistant members of the intestinal microbiota which may
cause fatal endogenous infections.
A fundamental and ambitious solution and countermeasure to these threats is the
development of novel pathogen-specific antiinfectives (pathoblockers), which
would not cause selection of resistance and which may not act against the
intestinal microbiota.
This project aims at the identification and development of inhibitors of bacterial
type III secretion systems for prevention and treatment of Salmonella infections,
and likely other pathogens with related type III secretion systems. The perspective
is to feed this research and development into a professional hit-to-lead process,
all in close collaboration with the TTU NAB and the TI Product Development
threat for the treatment of infections, in particular for treatment of GI pathogens,
as antibiotics affect the GI tract three-fold: emergence of resistance of GI
pathogens, disruption of colonization resistance of the intestinal microbiota, and
emergence of antibiotic-resistant members of the intestinal microbiota which may
cause fatal endogenous infections.
A fundamental and ambitious solution and countermeasure to these threats is the
development of novel pathogen-specific antiinfectives (pathoblockers), which
would not cause selection of resistance and which may not act against the
intestinal microbiota.
This project aims at the identification and development of inhibitors of bacterial
type III secretion systems for prevention and treatment of Salmonella infections,
and likely other pathogens with related type III secretion systems. The perspective
is to feed this research and development into a professional hit-to-lead process,
all in close collaboration with the TTU NAB and the TI Product Development
Involved staff
Managers
Interfaculty Institute of Microbiology and Infection Medicine (IMIT)
Interfaculty Institutes
Interfaculty Institutes
Institute of Medical Microbiology and Hygiene
Department of Diagnostic Laboratory Medicine, Hospitals and clinical institutes, Faculty of Medicine
Department of Diagnostic Laboratory Medicine, Hospitals and clinical institutes, Faculty of Medicine
Vice-Presidents
President’s Office, Central Administration (ZV)
President’s Office, Central Administration (ZV)
Cluster of Excellence: Controlling Microbes to Fight Infections (CMFI)
Centers or interfaculty scientific institutions
Centers or interfaculty scientific institutions
Other staff
Faculty of Medicine
University of Tübingen
University of Tübingen
Local organizational units
Interfaculty Institute of Microbiology and Infection Medicine (IMIT)
Interfaculty Institutes
University of Tübingen
University of Tübingen
Funders
Braunschweig, Niedersachsen, Germany